Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
Total Valuation
Evaxion Biotech has a market cap or net worth of $30.82M. The enterprise value is ―.
Market Cap$30.82M
Enterprise Value―
Share Statistics
Evaxion Biotech has 6,316,572 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,316,572
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Evaxion Biotech’s return on equity (ROE) is 6.40 and return on invested capital (ROIC) is -159.60%.
Return on Equity (ROE)6.40
Return on Assets (ROA)-0.85
Return on Invested Capital (ROIC)-159.60%
Return on Capital Employed (ROCE)-1.81
Revenue Per Employee72.70K
Profits Per Employee-229.35K
Employee Count46
Asset Turnover0.27
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Evaxion Biotech is ―. Evaxion Biotech’s PEG ratio is 0.12.
PE Ratio―
PS Ratio27.14
PB Ratio-54.94
Price to Fair Value-54.94
Price to FCF-7.01
Price to Operating Cash Flow0.00
PEG Ratio0.12
Income Statement
In the last 12 months, Evaxion Biotech had revenue of 3.34M and earned -10.57M in profits. Earnings per share was -9.80.
Revenue3.34M
Gross Profit3.34M
Operating Income-14.73M
Pretax Income-11.36M
Net Income-10.57M
EBITDA-9.79M
Earnings Per Share (EPS)-9.80
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Evaxion Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.41
52-Week Price Change-22.04%
50-Day Moving Average5.42
200-Day Moving Average3.06
Relative Strength Index (RSI)46.36
Average Volume (3m)436.15K
Important Dates
Evaxion Biotech upcoming earnings date is Apr 7, 2026, Before Open (Not Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateApr 7, 2026
Ex-Dividend Date―
Financial Position
Evaxion Biotech as a current ratio of 2.01, with Debt / Equity ratio of 181.22%
Current Ratio2.01
Quick Ratio2.01
Debt to Market Cap0.09
Net Debt to EBITDA-0.52
Interest Coverage Ratio-15.31
Taxes
In the past 12 months, Evaxion Biotech has paid -788.00K in taxes.
Income Tax-788.00K
Effective Tax Rate0.07
Enterprise Valuation
Evaxion Biotech EV to EBITDA ratio is -9.79, with an EV/FCF ratio of -7.40.
EV to Sales28.65
EV to EBITDA-9.79
EV to Free Cash Flow-7.40
EV to Operating Cash Flow-7.40
Balance Sheet
Evaxion Biotech has $10.57M in cash and marketable securities with $0.00 in debt, giving a net cash position of $10.57M billion.
Cash & Marketable Securities$10.57M
Total Debt$0.00
Net Cash$10.57M
Net Cash Per Share$1.67
Tangible Book Value Per Share-$0.08
Margins
Gross margin is 100.00%, with operating margin of -440.55%, and net profit margin of -316.00%.
Gross Margin100.00%
Operating Margin-440.55%
Pretax Margin-339.56%
Net Profit Margin-316.00%
EBITDA Margin-292.64%
EBIT Margin-310.80%
Analyst Forecast
The average price target for Evaxion Biotech is $12.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$12.33
Price Target Upside130.90% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast4455.07%
EPS Growth Forecast77.31%